Orion Animal Health receives FDA approval for Tessie® (tasipimidine oral solution)
ORION CORPORATION
PRESS RELEASE
MAY 12, 2026, AT 10:30 AM
Orion Animal Health receives FDA approval for Tessie® (tasipimidine oral solution)
Orion Corporation received approval from the U.S. Food and Drug Administration (FDA) on May 6, 2026, for Tessie® (tasipimidine oral solution), intended for the treatment of noise aversion and separation anxiety in dogs.
Tasipimidine is a molecule patented by Orion and a new active ingredient for veterinary use in the United States. It acts on the central nervous system by inhibiting the startle reflex, thereby producing a calming effect.
“This approval complements Orion’s portfolio of veterinary medicines developed for clearly identified clinical needs,” says Niclas Lindstedt, Executive Vice President, Orion Animal Health. “We have a long tradition of innovation and aim to leverage our scientific expertise to create new treatment options for veterinarians and to support animal welfare.”